Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study
复制标题
DOI：
10.1200/jco.2014.55.9898
复制
发表时间：
2015-05-01
影响因子：
45.3
通讯作者：
Chan, John K.
中科院分区：
文献类型：
--
作者：
Tewari, Devansu;Java, James J.;Chan, John K.
PurposeTo确定腹膜内（IP）化疗后晚期卵巢癌患者的长期生存率和相关预后因素，Patients and MethodsData from Gynecologic Oncology Group protocols 114 and 172进行回顾性分析。考克斯比例风险回归模型进行了统计分析。ResultsIn 876例患者，中位随访时间为10.7年。IP治疗的中位生存期为61.8个月（95% CI，55.5至69.5），而静脉治疗的中位生存期为51.4个月（95% CI，46.0至58.2）。IP治疗与死亡风险降低23%相关（校正风险比[AHR]，0.77; 95%CI，0.65 - 0.90; P = 0.002）。IP治疗改善了大体残留（
PurposeTo determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer.Patients and MethodsData from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox proportional hazards regression models were used for statistical analyses.ResultsIn 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8 months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; P = .002). IP therapy improved survival of those with gross residual (